Atezolizumab alone or in combination did not demonstrate a favorable risk-benefit profile in myelodysplastic syndrome
Sign Up to like & getrecommendations! Published in 2021 at "Blood Advances"
DOI: 10.1182/bloodadvances.2021005240
Abstract: Key Points Safety and efficacy data demonstrated that atezolizumab alone or with azacitidine did not support a favorable risk-benefit profile in MDS. The differential toxicity profile observed between patients with R/R and those with HMA-naïve… read more here.
Keywords: benefit profile; favorable risk; atezolizumab alone; risk benefit ... See more keywords